

an application for final commitment for a long-term loan or financial guarantee in excess of \$100 million (as calculated in accordance with Section 3(c)(10) of the Charter).

Comments received within the comment period specified below will be presented to the Ex-Im Bank Board of Directors prior to final action on this transaction.

Reference: AP087461XX.

Purpose and Use:

Brief description of the purpose of the transaction:

To support the export of U.S.-manufactured equipment for three cogeneration power plants in Saudi Arabia.

Brief non-proprietary description of the anticipated use of the items being exported:

To construct power plants to produce reliable electricity and steam.

To the extent that Ex-Im Bank is reasonably aware, the item(s) are not being exported to produce exports or provide services in competition with the exportation of goods or provision of services by a United States industry.

Parties:

Principal Supplier: General Electric Company.

Obligor: Power Generation Plant Company.

Guarantor(s): N/A.

Description of Items Being Exported:

The items being exported are turbine and turbine generator sets.

Information On Decision: Information on the final decision for this transaction will be available in the "Summary Minutes of Meetings of Board of Directors" on <http://exim.gov/newsandevents/boardmeetings/board/>.

Confidential Information: Please note that this notice does not include confidential or proprietary business information; information which, if disclosed, would violate the Trade Secrets Act; or information which would jeopardize jobs in the United States by supplying information that competitors could use to compete with companies in the United States.

DATES: Comments must be received on or before December 10, 2013 to be assured of consideration before final consideration of the transaction by the Board of Directors of Ex-Im Bank.

ADDRESSES: Comments may be submitted through Regulations.gov at WWW.REGULATIONS.GOV. To submit a comment, enter EIB-2013-0051 under the heading "Enter Keyword or ID" and select Search. Follow the instructions provided at the Submit a Comment screen. Please include your name,

company name (if any) and EIB-2013-0051 on any attached document.

Cristopolis A. Dieguez,

Program Specialist, Office of the General Counsel.

[FR Doc. 2013-27371 Filed 11-14-13; 8:45 am]

BILLING CODE 6690-01-P

FEDERAL COMMUNICATIONS COMMISSION

[AU Docket No. 13-53; DA 13-2057]

Tribal Mobility Fund Phase I Auction Rescheduled for February 25, 2014; Notice of Changes to Auction 902 Schedule Following Resumption of Normal Commission Operations

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: In this document, the Wireless Telecommunications and Wireline Competition Bureaus (the Bureaus) announce the rescheduling of Auction 902 and revise the dates and deadlines for the filing window for short-form applications and other auction processes.

FOR FURTHER INFORMATION CONTACT:

Wireless Telecommunications Bureau, Auctions and Spectrum Access Division: Patricia Robbins at (202) 418-0660. To request materials in accessible formats (Braille, large print, electronic files, audio format) for people with disabilities, send an email to fcc504@fcc.gov or call the Consumer and Governmental Affairs Bureau at (202) 418-0530 or (202) 418-0432 (TTY).

SUPPLEMENTARY INFORMATION: This is a summary of the *Auction 902 Rescheduling Public Notice* released on October 30, 2013. The complete text of the *Auction 902 Rescheduling Public Notice* and related Commission documents are available for public inspection and copying from 8:00 a.m. to 4:30 p.m. Eastern Time (ET) Monday through Thursday or from 8 a.m. to 11:30 a.m. ET on Fridays in the FCC Reference Information Center, 445 12th Street SW., Room CY-A257, Washington, DC 20554. The *Auction 902 Rescheduling Public Notice* and related Commission documents also may be purchased from the Commission's duplicating contractor, Best Copy and Printing, Inc. (BCPI), 445 12th Street SW., Room CY-B402, Washington, DC 20554, telephone 202-488-5300, fax 202-488-5563, or you may contact BCPI at its Web site: <http://www.BCPIWEB.com>. When ordering documents from BCPI, please

provide the appropriate FCC document number, for example, DA 13-2057 for the *Auction 902 Rescheduling Public Notice*. The *Auction 902 Rescheduling Public Notice* and related documents also are available on the Internet at the Commission's Web site: <http://wireless.fcc.gov/auctions/902/>, or by using the search function for AU Docket No. 13-53 on the Commission's Electronic Comment Filing System (ECFS) Web page at <http://www.fcc.gov/cgb/ecfs/>.

1. The Bureaus announce that Auction 902, the single-round reverse auction that will award up to \$50 million in one-time Tribal Mobility Fund Phase I support, will be conducted on February 25, 2014. The *Auction 902 Rescheduling Public Notice* also revises the previously-announced schedule of pre-auction deadlines for Auction 902.

2. The Auction 902 short-form application filing window opened at 12 noon ET on September 30, 2013, but was suspended on October 1, 2013, along with other Commission operations. Regular Commission operations were suspended from October 1 through October 16, 2013, due to a Government-wide lapse in funding. In the *Auction 902 Rescheduling Public Notice*, the Bureaus adopt schedule changes intended to give potential bidders and Commission staff additional time for planning and preparation for Auction 902 following the now-concluded 16-day suspension of regular Commission operations.

3. The following dates and deadlines will now apply to Auction 902: (1) A revised auction tutorial incorporating the revised dates and deadlines will be available (via Internet) by November 18, 2013; (2) the short-form application (FCC Form 180) filing window will reopen on November 18, 2013, at 12:00 noon ET; (3) the short-form application (FCC Form 180) filing window will close on December 5, 2013, at 6:00 p.m. ET; (4) a mock auction will be held on February 21, 2014; and (5) Auction 902 will be held on February 25, 2014. All other procedures, terms and requirements as set out in the *Auction 902 Procedures Public Notice*, 78 FR 56875, September 16, 2013, remain unchanged.

4. The Bureaus note that any information previously saved in a short-form application, FCC Form 180, during the period that the filing window was open prior to the suspension of the window on October 1, 2013, will be retained in the Commission's Auction system and will be accessible to the applicant when the short-form application filing window reopens.

Federal Communications Commission

Gary D. Michaels,

Deputy Chief, Auctions and Spectrum Access
Division, WTB.

[FR Doc. 2013-27444 Filed 11-14-13; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 12, 2013.

A. Federal Reserve Bank of Richmond (Adam M. Drimer, Assistant Vice President), 701 East Byrd Street, Richmond, Virginia 23261-4528:

1. *CapGen Capital Group III LLC and CapGen Capital Group III LP*, both in New York, New York; to acquire additional voting shares, for a total of 25 percent of, the voting shares of Seacoast Banking Corporation of Florida, and thereby indirectly acquire additional voting shares of Seacoast National Bank, both in Stuart, Florida.

Board of Governors of the Federal Reserve System, November 12, 2013.

Michael J. Lewandowski,

Associate Secretary of the Board.

[FR Doc. 2013-27373 Filed 11-14-13; 8:45 am]

BILLING CODE 6210-01-P

FEDERAL TRADE COMMISSION

Public Workshop: Follow-On Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition

AGENCY: Federal Trade Commission.

ACTION: Notice of workshop and request for comments.

SUMMARY: The Federal Trade Commission (“FTC” or “Commission”) announces it will hold a workshop to explore competition issues involving biologic medicines and follow-on biologics. The workshop will focus on the potential impact of state regulations and naming conventions on such competition, including how regulations may be structured to facilitate competition while still protecting patient health and safety. The experience of developing follow-on competition from small-molecule generic drugs will be considered and, as relevant, compared. Topics will include the circumstances under which potential entrants would be willing to invest in the development of follow-on biologics in order to use the abbreviated regulatory approval pathway created by federal legislation. The workshop will also survey the experience of other countries with regulatory systems that enable follow-on biologic competition. This Notice poses a series of questions about which the FTC seeks public comment. The FTC will take these comments into account in its examination of these topics.

DATES: The workshop will be held on December 10, 2013, in the FTC headquarters at 600 Pennsylvania Avenue NW., Washington, DC. The FTC workshop is free and open to the public and will also be webcast. Prior to the workshop, the Commission will publish an agenda and further information on its Web site. Comments in response to this notice must be received on or before March 1, 2014.

ADDRESSES: Interested parties may file a comment online or on paper, by following the instructions in the Request for Comment part of the **SUPPLEMENTARY INFORMATION** section below. Write “Workshop on Follow-On Biologics: Project No. P131208” on your comment, and file your comment online at <https://ftcpublic.commentworks.com/>

[ftc/biologicsworkshop](https://ftcpublic.commentworks.com/), by following the instructions on the web-based form. If you prefer to file your comment on paper, mail or deliver your comment to the following address: Federal Trade Commission, Office of the Secretary, Room H-113 (Annex X), 600 Pennsylvania Avenue NW., Washington, DC 20580.

FOR FURTHER INFORMATION CONTACT: Elizabeth Jex, Attorney Advisor, Office of Policy Planning, Federal Trade Commission, 600 Pennsylvania Avenue NW., Washington, DC 20580; (202) 326-3273; biosimilars@ftc.gov.

SUPPLEMENTARY INFORMATION: The Federal Trade Commission vigorously promotes competition in the health care industry through enforcement, study, and advocacy. Competition in health care markets benefits consumers by helping to control costs and prices, improve quality of care, promote innovative products, services, and delivery models, and expand access to health care goods and services. As addressed below, this proposed workshop is consistent with these FTC priorities.

I. Background: Follow-On Competition in Pharmaceutical Markets

In particular, the Commission has sought to protect competition among pharmaceutical products, including generic drugs providing price competition against brand-name drugs. Until relatively recently, the potential for follow-on competition was limited to products involving traditional “small-molecule” generic drugs. Producers of these drugs obtain approval from the Food & Drug Administration (“FDA”) pursuant to an abbreviated regulatory pathway established by the Hatch-Waxman Act.¹

Biologic medicines have now become among the most important pharmaceutical products in the United States. Biologics comprise the fastest growing sector within pharmaceuticals, and target such difficult to treat diseases as cancer, diabetes, and multiple sclerosis.² “Biologics” include, for

¹ See The Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301 *et seq.* (2011), as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, Public Law 98-417, 98 Stat. 1585 (codified as amended in scattered sections of 21 & 35 U.S.C.) (known as Hatch-Waxman), and the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Public Law 108-173, § 1112, 117 Stat. 2066, 2461-63 (codified at 21 U.S.C. 355).

² *Health Policy Brief: Biosimilars*, Health Affairs 1 (Oct. 10, 2013), http://healthaffairs.org/healthpolicybriefs/brief_pdfs/healthpolicybrief_100.pdf (“[Biologics] account for a substantial and increasing share of the pharmaceutical market and a growing share of health care costs”).